VJHemOnc was official media partner of the NYC-Miami Myeloma MRD 2020 Virtual Meeting which took place on the 8th of October 2020 and was organized by MMRF & Memorial Sloan Kettering Cancer Center.
The meeting brought together leading experts in multiple myeloma who discussed the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussion.

Watch the meeting on-demand below!

MRD in 2020: BMCTN consensus document

Luciano Costa, MD, University of Alabama at Birmingham

Watch Now
New trials with MRD focus. GRIFFIN, FORTE, ENDURANCE, MASTER, MANHATTAN

Benjamin Derman, MD, University of Chicago

Watch Now

Debates

Session 1: Should sustained MRD negativity be used to stop the treatment?

Yes: Nina Shah, UCSF and MMRC Steering Committee

No: Ajai Chari, MD, Icahn School of Medicine at Mount Sinai and MMRC Steering Committee

Watch Now
Session 2: Should MRD+ be used to re-initiate the treatment?

Yes: Elisabet Manasanch, MD Anderson

No: Amrita Krishnan, MD, City of Hope and MMRC Steering Committee

Watch Now
Session 3: Should MRD be used to guide delayed ASCT?

Continue with transplant: Noa Biran, MD, John Theurer Cancer Center

Hold off transplant: Paul Richardson, MD, DFCI

Watch Now

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter